Researchers from The University of Texas Medical Branch at Galveston, led by prostate cancer treatment pioneer Dr. Eric Walser, have shown that selectively destroying cancerous prostate tissue is as effective as complete prostate removal or radiation therapy while preserving more sexual and urinary function than the other treatments.
Two proteins work hand in hand to ensure that the tumor cells of neuroblastoma can grow at full speed. In Nature, a Würzburg research team shows how the proteins can do this.
Androgens stimulate prostate cancer cells to grow. Many drugs to target that cancer focus on stopping androgen biosynthesis or blocking the androgen receptor, or AR. Researchers have discovered a new function of the AR in prostate cells -- the AR is imported into and localizes to mitochondria of the cell, where it plays a novel role in regulating multiple mitochondrial processes.
Death rates from breast cancer are predicted to fall in all European Union (EU) countries in 2019 with the exception of Poland, according to new research published in the leading cancer journal Annals of Oncology. In their annual predictions for cancer deaths in the EU, Carlo La Vecchia and colleagues predict there will be 1.4 million deaths from all cancers in 2019.
Researchers theorized that adding adjuvant docetaxel, a cytotoxic chemotherapy drug, to the standard of care RT and long-term AS treatment could potentially improve overall survival and clinical outcomes for men with localized, high-risk prostate cancer.
A new tool to predict an individual's prognosis following a prostate cancer diagnosis could help prevent unnecessary treatment and related side effects, say researchers at the University of Cambridge.
A new risk model, easily accessible on a web interface, can predict the survival of non-metastatic prostate cancer patients, as well as the effect of different treatment approaches on survival. The modeling approach, developed by David Thurtle of the University of Cambridge, UK, and colleagues, is described this week in PLOS Medicine.
Scientists from Sanford Burnham Prebys Medical Discovery Institute (SBP) have identified how prostate cancer transforms into a deadly treatment-resistant prostate cancer subtype called neuroendocrine prostate cancer (NEPC) following treatment with anti-androgen therapy. Their findings -- which include the metabolic rewiring and the epigenetic alteration that drives this switch -- reveal that an FDA-approved drug holds potential as a NEPC treatment. The study was published in Cancer Cell.
Researchers from the University of Copenhagen have identified a specific mechanism that protects our cells from natural DNA errors -- an 'enemy within' -- which could permanently damage our genetic code and lead to diseases such as cancer. The study has just been published in one of the most influential scientific journals, Nature Cell Biology.
Scientists have discovered a defect in immune cells known as 'killer T cells' that explains their inability to destroy cancer tumors. The researchers believe that repairing this defect could make the cells much better cancer killers.